Provided herein are compositions, CO.sub.2-permeable/selective membranes and related methods of making and using the membranes. Ionically cross-linked poly(ether)-based membranes were prepared for applications relating to CO.sub.2. These films were studied for their thermal curing behavior using DSC. The resulting free-standing membranes have T.sub.gs near 64 C., T.sub.dS up to 230 C., and Young's modulus up to 4.2 MPa. These membranes showed CO.sub.2 permeabilities of 84-110 Barrer and CO.sub.2/N.sub.2 selectivity of 20-40.

The present invention discloses novel difunctional monomers compound containing pendant clickable furyl group of formula (I), process for the preparation and polymers prepared there from. ##STR00001##
wherein,
X is selected from COOCH.sub.3, COOH, CON.sub.3, NCO, CONHNH.sub.2, CH.sub.2OH n is selected from 2 to 12.

The present invention discloses novel difunctional monomers compound containing pendant clickable furyl group of formula (I), process for the preparation and polymers prepared there from. ##STR00001##
wherein,
X is selected from COOCH.sub.3, COOH, CON.sub.3, NCO, CONHNH.sub.2, CH.sub.2OH n is selected from 2 to 12.

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, ?-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.

##STR00001##

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, ?-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.

##STR00001##

The invention relates to a method for preparing polyarylethersulfone-polyalkylene oxide block copolymers (PPC) comprising the polycondensation of a reaction mixture (R.sub.G) comprising the components: (A1) at least one aromatic dihalogen compound, (B1) at least one aromatic dihydroxyl compound, (B2) at least one polyalkylene oxide having at least two hydroxyl groups, (C) at least one aprotic polar solvent and (D) at least one metal carbonate,
where the reaction mixture (R.sub.G) does not comprise any substance which forms an azeotrope with water.

A perfluoropolyether-based rubber composition which gives cured objects excellent in terms of heat resistance, low-temperature resistance, organic-solvent resistance, and acid resistance, the rubber composition being characterized by comprising (a) a linear perfluoropolyether compound having a number-average molecular weight of 1,000-100,000 and including at least two azido groups in the molecule and a divalent perfluoroalkyl ether structure in the main chain and (b) a linear perfluoropolyether compound having at least three ethynyl groups in the molecule.

A perfluoropolyether-based rubber composition which gives cured objects excellent in terms of heat resistance, low-temperature resistance, organic-solvent resistance, and acid resistance, the rubber composition being characterized by comprising (a) a linear perfluoropolyether compound having a number-average molecular weight of 1,000-100,000 and including at least two azido groups in the molecule and a divalent perfluoroalkyl ether structure in the main chain and (b) a linear perfluoropolyether compound having at least three ethynyl groups in the molecule.

The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety comprising prostaglandin analogues. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.

The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety comprising prostaglandin analogues. The present invention also relates to methods for preparing the polymer conjugates using click chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the treatment of glaucoma.